Last updated on February 2018

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor


Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Clinical Study Identifier: NCT02617134

Contact Investigators or Research Sites near you

Start Over

Lin Yang, Ph.D.

PersonGen Biomedicine (Suzhou) Co., Ltd.
Suzhou, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.